Unknown PHASE4 INTERVENTIONAL 1-arm NCT03631134

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal

Sponsor: Nanjing First Hospital, Nanjing Medical University

Updated 5 times since 2018 Last updated: Aug 12, 2018 Started: Aug 15, 2018 Primary completion: Jan 15, 2019 Completion: Jan 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Type2 Diabetes and is currently ongoing. Nanjing First Hospital, Nanjing Medical University leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Sep 2018 — Sep 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing First Hospital, Nanjing Medical University

Data source: Nanjing First Hospital, Nanjing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.